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Paclitaxel-loaded niosomes for intravenous administration: pharmacokinetics
and tissue distribution in rats
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Background/aim: The purpose of this study was to investigate and compare the pharmacokinetic behavior and tissue distribution of
paclitaxel, delivered as commercial preparation Taxol or through Span 40 niosomes, after intravenous injection to rats.
Materials and methods: Paclitaxel-loaded Span 40 niosomes were prepared using the thin-film method. An HPLC method was
developed and validated for paclitaxel determination in rat plasma and tissues.
Results: The area under the curve value of the niosome-recipient group (3.22 ± 0.255 µg h/mL) was significantly higher compared to
that of the Taxol group (0.725 ± 0.163 µg h/mL). The mean residence time and the elimination half-life of paclitaxel were 1.66 ± 0.133
h and 1.15 ± 0.085 h for Taxol administration, respectively. The elimination half-life (7.63 ± 0.380 h) and the mean residence time (11.0
± 0.6 h) of paclitaxel were significantly increased, and a pronounced delay was observed in general excretion of paclitaxel from plasma
(0.0925 ± 0.00490 h–1) after niosomal administration. The spleen was the main tissue that accumulated paclitaxel from both niosomes
and Taxol.
Conclusion: The findings of this study show that niosomal formulation might be a useful drug delivery system for intravenous
administration of paclitaxel.
Key words: Niosomes, Span 40, paclitaxel, pharmacokinetics, tissue distribution

1. Introduction
Paclitaxel (PCT) is a chemotherapeutic agent used as a
first-line treatment for a wide range of cancers, such as
lung, ovarian, breast, prostate, head, and neck cancers,
and AIDS-related Kaposi sarcoma. The first commercially
available preparation of PCT on the drug market is Taxol.
Taxol is a nonaqueous solution of PCT formulated in a
1:1 combination of the solubilizing agent Cremophor
EL (polyethoxylated castor oil) and dehydrated ethanol,
which is intended for dilution with a suitable parenteral
fluid prior to intravenous (i.v.) infusion (1,2). However,
the formulation of PCT is still a problem that hinders its
use. Severe hypersensitivity reactions, neurotoxicity, and
nephrotoxicity are observed after i.v. infusion of PCT and
are a result of the Cremophor EL, rather than drug itself.
Moreover, upon the contact of the PCT formulation with
polyvinyl chloride infusion sets, Cremophor EL causes
leaching of the plasticizer diethylhexylphthalate. Another
problem with the formulation is the precipitation of PCT
after dilution in the infusion solutions (3–5). Additionally,
* Correspondence: nyuksel@pharmacy.ankara.edu.tr

it causes serious side effects after systemic administration
due to unspecific biological distribution.
There have been studies on several formulation
approaches to enhance the solubility of PCT, which is
highly hydrophobic; to control its biological distribution;
and to avoid and eliminate the problems caused by its
formulation. The first outcome of these studies was
Abraxane, which was approved by the FDA in 2005.
Abraxane is lyophilized powder and contains 800 mg of
albumin per 100 mg of paclitaxel. After reconstitution with
an isotonic sodium chloride solution before i.v. infusion,
the resulting injectable suspension includes PCT-bound
albumin nanoparticles that have a size of approximately
130 nm. Paclitaxel passage through the endothelial cells is
improved due to albumin, and this was attributed to the
gp-60 albumin receptor. The albumin-binding protein
SPARC (secreted protein acidic rich in cysteine) leads to
the enhanced PCT accumulation in the tumor site. This
protein is overexpressed in breast carcinoma cells, and
Abraxane is used to treat advanced metastatic breast
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cancer (6,7). Afterwards, a polymeric micelle formulation
of PCT, Genexol-PM, and a liposome formulation, Lipusu,
were commercialized in Korea and China, respectively.
These formulations provide the PCT solubility without
using toxic solvents, while they decrease the toxic side
effects and improve the drug’s therapeutic efficacy by a
better drug distribution (8–11). The phase III clinical trials
of a polymeric conjugate of PCT with a water-soluble
polymer polyglutamic acid, Opaxio (paclitaxel poliglumex;
formerly called Xyotax), is ongoing. The preclinical studies
revealed that Opaxio can more effectively target PCT to
the tumorous tissue compared to standard PCT. This is
explained by the leakage of PCT conjugate through leaky
tumor vessels and its entrapment in the tumor site. The
proteinic polymer is metabolized inside the tumor cell and
then releases PCT (12). Other PCT delivery systems such
as solid lipid nanoparticles, nanoparticles of biodegradable
polymers, micellar nanocarriers, nanohydrogels, and
dendrimers have also been intensively investigated (1,13–
19).
In aqueous mediums, nonionic surfactants are known
to form niosomes, which are closed, bilayered structures
that vary in size from a few hundred nanometers to
several micrometers (20). Depending on the preparation
technique, niosomes can be in small unilayered or
multilayered forms. The hydrophilic head groups of the
nonionic surfactants are placed in the outer and inside
part of the vesicle, and the hydrophobic groups face
each other inside the bilayer (Figure 1). Thus, while the
hydrophilic active agents are entrapped inside the vesicle,
the hydrophobic agents are entrapped inside the bilayers
(21,22). The first niosome formulation was developed in
1975 and was patented as an antiaging cosmetic product by

L’Oréal. Afterwards, the studies for the usage of niosomes
as drug delivery systems started.
In a previous study, PCT-carrying niosomes were
prepared with various surfactant types (Tween 20 and
60; Span 20, 40, and 60; Brij 76, 78, and 72) by using the
thin-film technique. The in vitro characterization studies
on these formulations revealed the formation of nanosized
niosomes with varying surface charges between –40 and
–53 mV. The Span 20, 40, and 60 and Brij 72 surfactants,
which have low hydrophile-lipophile balance values, were
found to be more appropriate for the entrapment of PCT
in niosomes (5). Among these formulations, the niosomes
prepared with Span 40 were further evaluated using
differential scanning calorimetry and X-ray diffractometry
to observe the interaction between PCT and other
formulation excipients. The outcomes showed that PCT
was in an amorphous form inside the niosomes; the highly
lipophilic active agent was loaded inside the bilayer lipid
membrane by partition and thus provided slow in vitro
PCT release (23).
The purpose of the present work was to investigate the
pharmacokinetic behavior and distribution of PCT in the
tissues from the PCT-loaded Span 40 niosomes compared
to a commercially available i.v. preparation, Taxol, each
administered intravenously to rats.
2. Materials and methods
2.1. Materials
PCT, cholesterol, and dicetyl phosphate (DCP) were
purchased from Sigma-Aldrich (Milwaukee, WI, USA).
Docetaxel and Span 40 (sorbitan monopalmitate) were
bought from Fluka (Buchs, Switzerland). Acetonitrile,
chloroform, methanol, and t-butyl methyl ether were
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Hydrophilic Hydrophobic
Drug
Drug
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Figure 1. Schematic representation of niosomes (TEM: transmission electron microscopy; SEM: scanning electron
microscopy).
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purchased from Merck (Darmstadt, Germany). Sodium
chloride was bought from Carlo Erba (Milan, Italy).
Milli-Q water was used in the experiments (Millipore,
MA, USA). Taxol (Bristol Mayer Squibb Inc., İstanbul,
Turkey; Lot No. 8C46893) was purchased from a pharmacy
(Ankara, Turkey).
2.2. PCT formulations
Niosomes were prepared using the thin-film method (5).
Briefly, Span 40, cholesterol, and DCP were mixed at the
molar concentrations of 2.97 × 10–3 : 2.97 × 10–3 : 2.5 × 10–3
in chloroform. PCT solution in acetonitrile (0.234 mM)
was added to the obtained organic solution. The organic
solvents of the solution were removed by Rotavapor (Buchi
200, Labortechnik AG, Flawil, Switzerland). The thin-lipid
film produced on the inner surface of a round-bottomed
flask was hydrated with ultrapure water at 60 °C. After the
separation of unentrapped PCT by ultracentrifugation at
150,000 × g for 1.5 h at 4 °C (Beckman Optima XL-100K,
Germany), the PCT-loaded niosome pellet was rehydrated
in a certain amount of ultrapure water. The obtained
niosome suspension was kept in 5 ± 3 °C. The preparation
process was performed under aseptic conditions. The
particle size and zeta potential of the formulations were
determined by dynamic light scattering and laser Doppler
anemometric methods, respectively, using a Zetasizer
(Malvern Zetasizer nanoZS, Malvern Instruments, UK).
The characteristics of the preparations used in the in vivo
study are as follows.
2.2.1. Span 40 niosomes
Particle size range and average particle size: 50–300 nm
and 133 ± 6 nm
Zeta potential: –65.6 ± 1.2 mV
Fraction of PCT in niosomes: 3.64% (w/w)
2.2.2. Taxol formulation
PCT…………………….....................…......…………..6 mg
Ethanol: Cremophor (1:1 w : w)….q.s...1 mL
After dilution: Particle size range and average particle size:
5.6–24.4 nm and 13.08 ± 0.0415 nm
Zeta potential: –5.90 ± 0.989 mV
2.3. Pharmacokinetic and tissue distribution studies in
rats
2.3.1. Animals
The animal studies were approved by the Local Ethics
Committee of Ankara University for Animal Experiments
(decision number 2007-10-32). Male Wistar rats weighing
200–250 g were used in the studies. The animals were kept
in cages under normal conditions and fed with standard
diets in the pellet forms. The rats were fasted 24 h before
starting the experiments while water was given to them ad
libitum.

2.3.2. Dosage schedule, blood sampling, and tissue
removal
For the pharmacokinetic studies, the animals were divided
randomly into 2 groups. Group I received a single dose of
Taxol (2.5 mg PCT/kg) (n = 6). Group II received a single
dose of PCT-loaded Span 40 niosomes (2.5 mg PCT/kg)
(n=6).
Both formulations were diluted to 1 mL with ultrapure
water in order to have the required doses of the drug (2.5
mg/kg) and were injected to the rats’ femoral veins. Blood
samples of 200 µL were collected from the tail veins of
the rats at the time points of 0.05, 0.25, 0.5, 1, 2, 4, 6, 10,
and 24 h into ice cold heparinized test tubes. Plasma was
separated from blood samples by centrifugation at 10,000
rpm for 10 min and stored at –60 °C until drug analysis.
After collecting blood samples from rats at h 24,
the rats were anesthetized with ether and sacrificed
via exsanguination. The liver, spleen, lungs, heart, and
intestines were excised and rinsed thoroughly with saline 3
times. Tissue samples were blot-dried, weighed, and stored
at –60 °C until drug analysis.
2.4. HPLC analysis of PCT in plasma and tissue samples
Standard solutions of PCT were prepared in acetonitrile
at different concentrations. After gentle thawing, blank
plasma samples (100 µL) were spiked with 25 µL of PCT
solutions, 10 µL of internal standard (docetaxel 15 µg/
mL), and 50 µL of methanol, and then 1 mL of t-butyl
methyl ether was added. The mixtures were centrifuged
at 15,000 rpm, and 1 mL of supernatant from each of
them was taken into a test tube. After evaporation of the
organic solvent at 40 °C, the residue was dissolved in
100 µL of methanol and was injected in the column of
HPLC system (Agilent 1100, Waldborn, Germany). The
chromatographic separation was achieved on a Waters
Symmetry C18 reverse-phase column (150 mm × 4.6
mm, 5 µm) at 25 °C. The mobile phase was a mixture of
acetonitrile (with 0.1% formic acid, v/v) and water (46:54,
v/v). The UV detection was performed at a wavelength of
195 nm, the flow rate was 1.0 mL/min, and the injection
volume was 25 µL. The calibration curve was constructed
by plotting PCT concentrations versus the peak area ratios
of PCT to docetaxel (24). PCT was extracted from the
blood and tissue samples according to the procedure given
in Figure 2. The extracts were analyzed by HPLC, and the
drug concentrations were calculated from the obtained
calibration curve.
2.4.1. Method validation
The method was validated in terms of accuracy,
precision, reproducibility, repeatability, intermediate
precision, specificity, linearity, and limit of detection and
quantification according to ICH and FDA guidelines for
the bioanalytical method validation (25,26).
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Tissue sample

Extraction flow chart
Blood sample

Add 20 mL saline and
homogenize by ultraturrax

Centrifuge at 15,000 rpm
for 15 min

Take 1 mL tissue homogenate

Add 25 µL acetonitrile,
10 µL docetaxel solution (15 µg/mL),
50 µL methanol and vortex for 1 min

Add 250 µL acetonitrile,
100 µL docetaxel solution (15 µg/mL),
500 µL methanol and vortex for 1 min

Add 1 mL tertiary butyl methyl ether ,
vortex for 1 min,
keep in shaker bath at 120 rpm for 10 min

Add 2 mL tertiary butyl methyl ether ,
vortex for 1 min,
keep in shaker bath at 120 rpm for 10 min

Centrifuge at 15,000 rpm
for 15 min

Centrifuge at 15,000 rpm
for 15 min

Residue
Take 2 mL supernatant
and evaporate the
solvent at 40 °C

Take 1 mL supernatant
and evaporate the
solvent at 40 °C
Add 100 µL
methanol for
plasma or 1 mL for
tissue extract

Analyze by
HPLC

Figure 2. Procedure for the extraction of PCT from blood and tissue samples after i.v.
administration of niosome dispersion and Taxol to the rats.

2.5. Calculation and statistical analysis
PCT formulations were evaluated through the following
parameters:
• AUC0→ h : Trapezoidal area under the curve of plasma
concentration vs. time, from time 0 to last sampling
time, 24 h
• Cmax : Maximum plasma concentration
• MRT0→24h : Mean residence time
• Lz : General excretion of drug from plasma
• T1/2 : Elimination half life
• Frel : Relative bioavailability as (AUCniosome/AUCTaxol) ×
100
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The pharmacokinetic parameters were calculated by
Kinetika ver. 5.0 (Thermo Fisher Scientific, Waltham, MA,
USA) using a noncompartmental method. The maximum
plasma concentration (Cmax) was directly obtained from
plasma concentration–time graphs. The parametric
statistical evaluation of the data was performed through
one-way variance analysis followed by Tukey multiple
comparisons employing SPSS 9.0 for Windows (SPSS Inc.,
Chicago, IL, USA).
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Detector response

3. Results
3.1. Quantitative analysis of PCT in biological samples
and method validation
The HPLC method was described in our previous studies
(5,24). The method was fully validated and used for the
determination of PCT in blood and tissue samples after
i.v. administration to the rats. In HPLC methods, accuracy
and precision can often be improved by using an internal
standard. An internal standard compensates for the
potential changes in the sample size or concentration
originating from instrumental variations by correcting
fluctuations in detector response (27). Docetaxel (DCT)
was used as an internal standard in this study. Samples
were prepared by spiking the rat plasma with known
concentrations of PCT and DCT and then extracting
the drug according to the procedure given in Figure 2.
The retention times were 11.5 min for PCT and 9.91 min
for DCT (Figure 3). The calibration curve obtained by
plotting the peak area ratio of PCT to DCT versus PCT
concentrations became linear over the range of 0.04–0.60
µg/mL with the determination coefficient (r2) of 0.9905.
The limits of quantification and detection were 16.18 × 10-3
µg/mL and 5.34 × 10-3 µg/mL, respectively.
The accuracy of a method describes the proximity
of mean test results to the true concentrations, while
precision describes the proximity of each measurement
result obtained from the procedure, which is repeatedly
applied to the biological samples. The accuracy and
precision by repeatability were indicated by performing 6
measurements on each of 3 different concentrations of PCT
(low: 0.1 µg/mL, medium: 0.2 µg/mL, and high: 0.5 µg/
mL), prepared by spiking the solutions into the rat plasma
and calculating the concentrations by the calibration
curve of the drug. Furthermore, the precision was also
determined using intermediate precision. The intermediate
precision is established depending on the variations, such
as different days and analysts, to see the effects of random
events on the precision of the analytical procedure (25).
Three different concentrations of PCT (low, medium, and
high) in rat plasma were prepared, and each of them was
measured 6 times by HPLC on different days (1st, 2nd, and
3rd days) by the same analyst. Relative standard deviations

of these determinations were quite low at the level of 2%,
showing adherence to the FDA guideline (26). Blank
samples of rat plasma and tissues as a biological matrix
and the solvents that were used in the analytical method
were handled the same as in the extraction procedure
in Figure 2 and analyzed by HPLC. The peaks from the
blank samples did not interfere with those of the samples
containing PCT and DCT, demonstrating the selectivity of
the analytical method.
3.2. Pharmacokinetic and tissue distribution studies
Figure 4 shows the measured plasma concentrations of
PCT versus time after i.v. administration of the niosome
formulation and of the commercially available i.v.
preparation, Taxol, given to the rats in a single dose of
2.5 mg/kg The plasma concentrations of PCT obtained
within the first 2 h after drug administration were similar
in both administration groups, as seen in the inset of
Figure 4. Then a fast decline in PCT plasma concentration
occurred in the rats administered Taxol, with the final PCT
measurement occurring after 6 h. On the other hand, the
PCT plasma curve of the rats administered PCT-loaded
Span 40 niosomes formed a plateau at an almost steadystate concentration starting at 2 h and lasting until 24 h.
The pharmacokinetic parameters calculated from the
plasma concentrations vs. time curves are given in the
Table. The maximum plasma concentrations (Cmax values)
were 0.754 ± 0.123 µg/mL and 0.872 ± 0.187 µg/mL for
Taxol and the niosomes, respectively. The difference
between the Cmax values was not statistically significant (P
> 0.05). The value of area under the curve, AUC0–24, was
0.725 ± 0.163 µg h/mL in the group that received Taxol.
When this value is compared to the AUC0–24 value of the
group that received niosomes (3.22 ± 0.255 µg h/mL), the
niosomes were found to be significantly more effective for
enhancing the bioavailability of PCT (P < 0.001). In the rat
group that received Taxol, the mean residence time (MRT)
and the elimination half-life (T1/2) of PCT were estimated
as 1.66 ± 0.133 h and 1.15 ± 0.085 h, respectively. The MRT
and T1/2 values of PCT were 11.0 ± 0.6 h and 7.63 ± 0.380
h, respectively, in the rat group that received niosomes.
There were statistically significant differences between
these values (P < 0.001). The general excretion rate of drug

1

0
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6

8

2

10

Time (min)

Figure 3. The HPLC chromatogram demonstrating the (1)
docetaxel and (2) PCT peaks obtained for PCT calibration in the
plasma.
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Plasma concentration (µg/mL)

1.2
1,2

Plasma concentration (µ g/mL)

1,2
1.2

1

0.8
0,8
0.6
0,6

1

0.4
0,4

0.8
0,8

0.2
0,2

0.6
0,6

0

0.4
0,4

-0

0,50
0.5

1,001
Time (h)

1,50
1.5

2,002

0.2
0,2

00
-0

5
5,00

10
10,00

15
15,00
Time (h)

Taxol®

20
20,00

Niosomes

Figure 4. Plasma concentration of PCT after i.v. administration of Span 40 niosomes
and Taxol. The inset represents the PCT plasma concentrations in the first 2 h.

Table. Pharmacokinetic parameters of PCT calculated from Taxol solution and PCT-loaded Span 40 niosomes after i.v. administration
in rats at a single dose of 2.5 mg/kg.

N=6

Cmax
(µg/mL)

MRT24
(h)

AUC0–24
(µg h/mL)

T1/2
(h)

Lz
(h–1)

Taxol

Niosome

Taxol

Niosome

Taxol

Niosome

Taxol

Niosome

Taxol

Niosome

1

0.618

1.32

0.729

3.22

2.11

9.46

1.47

6.55

0.474

0.106

2

0.552

0.429

0.331

2.83

1.19

13.3

0.822

9.23

0.84

0.0752

3

1.20

0.479

1.48

2.69

1.72

11.3

1.20

7.86

0.581

0.0885

4

0.871

0.573

0.569

3.93

1.91

9.57

1.32

6.63

0.524

0.105

5

0.362

1.51

0.723

2.61

1.57

10.5

1.09

7.29

0.637

0.0952

6

0.919

0.923

0.519

4.02

1.46

11.8

1.01

8.19

0.685

0.0848

Mean

0.754

0.872

0.725

3.22

1.66

11.0

1.15

7.63

0.624

0.0925

SE

0.123

0.187

0.163

0.255

0.133

0.600

0.085

0.380

0.0532

0.0049

95% Confidence interval
LL

0.438

0.391

0.308

2.56

1.32

9.46

0.910

6.55

0.487

0.0126

UL

1.07

1.35

1.14

3.87

2.00

12.5

1.39

8.70

0.760

0.105

Significance
P

0.608

0.000*

0.000*

LL: Lower limit; UL: Upper limit; SE: Standard error. * : P < 0.001.

1408

0.000*

0.000*

SEZGİN BAYINDIR et al. / Turk J Med Sci
from plasma, the Lz value, determined from the Taxoladministered group was found to be significantly higher
(0.624 ± 0.0532 h–1) than the value determined from the
niosome-administered group (0.0925 ± 0.00490 h–1) (P <
0.001).
The tissue distribution of PCT in the liver, intestines,
kidneys, heart, lungs, and spleen after i.v. administration
of Taxol and Span 40 niosomes to the rats at 24 h is shown
in Figure 5. The concentrations of PCT in the Taxol
group seem to be higher in all tissues in comparison to
the niosome group, and the values calculated for liver
(P < 0.05), heart (P < 0.05), and kidneys (P < 0.10) were
statistically significantly different. The accumulation of
PCT was substantially high in the spleen compared to the
other tissues after both niosome and Taxol administration.

materials; and sterilization by membrane filtration,
autoclaving, and gamma irradiation (21,30).
Concerning the advantages of the niosomal drug
delivery systems, our objective was to develop an alternative
formulation that could overcome the poor aqueous
solubility of PCT and avoid the use of Cremophor EL, which
causes serious adverse effects in the clinical application
of Taxol. Different classes of nonionic surfactants have
been used for the preparation of niosomes. The diversity
of the surfactants offers a chance to design the niosomes
to meet our expectations. The selection of the surfactants
highly depends on the in vitro performance and qualities
of the niosomes, such as drug-loading efficiency, particle
size, and drug release (5,23,24). In this report, PCTloaded niosomes were prepared with the most appropriate
surfactant, Span 40, that we had previously determined
with in vitro studies. The pharmacokinetic parameters
and tissue distribution of PCT upon i.v. administration
were investigated by comparing these values with Taxol
administration.
The HPLC method, which was used to measure PCT in
plasma and tissue samples, was validated. The linearity range
covered the studied concentrations, and PCT was separated
from the endogenous components without any interference
(Figure 3). Figure 4 shows the mean plasma concentrations
of PCT against time, measured after i.v. administration of
niosomes and Taxol. The early time points on the graph
show that the decrease in PCT concentration was fast for
both preparations initially, and at later time points the
decrease slowed down for the niosomes. The first part of
the graph covers the distribution phase of the PCT from the
plasma to the tissues, which also includes elimination. After
attaining steady-state concentrations between plasma and
tissue, PCT concentrations decrease only by elimination.
Upon oral administration of the same niosome formulation,
a similar plasma concentration–time profile was obtained
following the PCT absorption stage (24).

4. Discussion
Liposomes have been widely studied as drug delivery
systems in the vesicular system, and there are currently
numerous liposome preparations on drug market (28).
However, some hurdles have been faced in regard to the
pharmaceutical development of these systems. These
obstacles include the poor quality of the phospholipids
used for the preparation of liposomes, their expensiveness,
chemical stability problems such as hydrolysis and
oxidation that lead to too-short shelf life, and scaleup problems. Due to these issues, niosomes have been
presented as an alternative system (21,29).
Niosomes behave similarly to liposomes in vivo.
Besides the general advantages of drug delivery systems,
they have distinct advantages such as control of shape, size,
composition, and fluidity when required; biodegradability,
biocompatibility, and nonimmunogenicity to the body;
targeting drugs to various organs; sustained drug release;
entrapment of both hydrophilic and hydrophobic drugs;
easy handling and storage conditions; suitability for
industrial manufacture due to relatively low cost of
2500

®

Taxol

PCT (ng/g)

2000

Niosomes

1500
1000
500

**

*

*

0

Figure 5. Tissue distribution of PCT after i.v. administration of
Taxol and Span 40 niosomes at 24 h (*: P < 0.05; ** : P < 0.1).
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Pharmacokinetic parameters of PCT from the niosome
formulation were significantly better than the results from
the Taxol group (Table). The AUC value of PCT from
the group administered niosomes was 4.44 times higher
compared to the group administered Taxol. The MRT
value of PCT is 11 h, and it was 6.6 times higher than that
of Taxol. Similarly, the PCT elimination half-life T1/2 value
after the niosome application was 6.6 times higher than
the half-life of Taxol. Therefore, the coefficient of general
excretion of the drug was 6.7 times lower than in the Taxol
group.
The long blood-circulation time of the niosomes was
related to the small particle size of the niosomes, which
was 133 ± 6 nm. On the other hand, the size of the micelles
formed upon dilution of Taxol with water was 13.08 ±
0.0415 nm. The literature data show that nanoparticles
with small sizes (40–300 nm or 200 nm) have the ability
to escape from the reticuloendothelial system and thus
exhibit a slower clearance rate (31). The importance
of particle size is very well known for sustained drug
release and targeted delivery of drugs. Tumor cells display
leaky blood vessels and poor lymphatic drainage. While
unattached drugs may distribute nonspecifically into the
body, nanocarriers can accumulate specifically into the
tumor tissue through the enhanced permeability effect of
the tumor vasculature (32,33). The prolonged circulation
time and the small particle size of PCT-loaded Span 40
niosomes demonstrated the potential of niosomes for
the passive targeting of cancer cells. This situation can be
further elucidated with in vivo experiments on tumorbearing animals. The long blood-residence time also
demonstrated the niosome stability. The stability of a
nanocarrier is important for its eventual accumulation in
the tumor tissue (31). Similar pharmacokinetic behavior
was observed upon i.v. administration of PCT-loaded
pegylated polymeric micelles as another nanoparticulate
drug-delivery system. The investigators compared the
results with a commercially injectable PCT product and
observed higher AUC, longer systemic circulation times,
and slower plasma elimination rates upon administration
of micellar formulation. Therefore, they suggested the
usage of polymeric micelles due to their long-circulating
property.
One of the major limitations of cancer therapy is the
nonspecific systemic distribution of anticancer agents,
which can lead to severe side effects in sensitive healthy
tissues. Therefore, tissue distribution studies on the vital
organs were conducted (16,34). Figure 5 shows tissue
distribution of PCT after i.v. administration of Taxol and
PCT-loaded niosomes at the end of 24 h. In the Taxoladministered rat group, PCT was distributed widely
to all of the examined tissues, although it could not be
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detected in plasma beyond 6 h after administration.
However, PCT-loaded Span 40 niosomes clearly altered
the tissue distribution of PCT in rats. The accumulated
amounts of PCT in the liver, kidneys, and heart were
significantly reduced in the niosome-administered group.
This result emphasized the selective tissue distribution of
the niosomes. Additionally, lower accumulation of PCT
in the heart and kidneys might be an important piece of
evidence in terms of the prevention of cardiotoxicity and
nephrotoxicity observed during chemotherapy. The spleen
accumulations of the drug were higher than in the other
tissues in both PCT formulations. This result reveals that
PCT is filtered by the spleen during the circulation in the
blood and suggests the potential usage of niosomes for
specific drug delivery to the spleen.
There are several studies in which niosomes were
evaluated as drug carrier systems for anticancer agents
such as hydroxycamptothecin (HCPT), doxorubicin,
methotrexate, 5-fluorouracil, cisplatin, and pentoxifylline
(35–44). The results obtained in the present study agree well
with those of the previous studies. The pharmacokinetics
and tissue distribution of anticancer agent HCPT-loaded
Span 60 niosomes, pegylated niosomes, and an active
targeting agent, transferrin-bound pegylated niosomes,
were investigated following their i.v. administration in
tumor-bearing mice in a model compared with a plain
drug solution. In the group given the HCPT solution,
the HCPT was removed very rapidly from the blood
circulation. The plasma levels of HCPT for the Span 60
niosomes remained high for the longest time, followed
by pegylated niosomes and, finally, transferrin-pegylated
niosomes. The tissue distribution of HCPT from the
niosome preparations showed the highest concentration
in the spleen and tumor tissues. The liver, lungs, kidneys,
heart, and brain were in the same rank for niosomes; the
lowest accumulation values were observed for the HCPT
solution (36). In another study, doxorubicin as a polymeric
conjugate was entrapped in niosomes prepared with
hexadecyl diglycerol ether surfactant and polyethylene
glycol compound Solulan C24. The plasma clearance of
the polymeric conjugate-loaded niosomes with a mean
size of 420 nm was rapid, and the niosomes were uptaken
mainly by the liver and spleen of the reticuloendothelial
system. The rapid plasma clearance was different in the
present study, and this might be ascribed to the different
composition and larger particle size of the niosomes.
However, the sustained release of the free drug in the liver
by the niosomes proposes the usefulness of niosomecontaining prodrugs in the treatment of liver-related
diseases (37).
In this study, PCT-loaded Span 40 niosomes with a
mean size of 133 nm were prepared by thin-film method.
A simple, sensitive HPLC method was developed and
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validated for the determination of PCT from Span
40 niosomes in rat plasma and tissues. The niosomes
increased the AUC value of PCT by 4.44-fold compared
to the commercial preparation of PCT, Taxol. Likewise,
when this result was compared with the previous results
obtained upon oral administration of the niosomes, there
was an 8.09 times improvement in AUC values (24). The
prolonged detection of PCT in plasma revealed the slow
release of the drug from niosomes. According to the tissue
distribution study, niosomes were removed from the blood
by the spleen and the amounts of PCT from niosomes in
the liver, kidneys, and heart were significantly lower than
those obtained from Taxol. These results provide strong

support for the targeting of niosomes to tumor tissues
and the reduction of side effects to healthy tissues. Further
evaluations of niosomes in tumor-bearing mice have been
planned and will be beneficial for the demonstration of
passive tumor targeting ability of PCT-loaded niosomes.
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